SURVANTA 25MG INJECTION 8 ML

How SURVANTA 25MG INJECTION 8 ML Works

• SURVANTA (beractant) is a lung surfactant used to prevent and treat Respiratory Distress Syndrome (RDS) in premature infants. RDS occurs because premature babies often lack sufficient natural surfactant, a substance that helps the lungs inflate and exchange oxygen and carbon dioxide effectively. SURVANTA works by replenishing this missing surfactant, improving lung function and making it easier for the baby to breathe.
• The active ingredient in SURVANTA, beractant, is a modified natural bovine (cow) lung extract. It contains phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins SP-B and SP-C. These components work together to mimic the function of natural human surfactant. Phospholipids, particularly dipalmitoylphosphatidylcholine (DPPC), are the main surface-active components responsible for reducing surface tension in the alveoli (tiny air sacs in the lungs).
• When SURVANTA is administered into the infant's lungs via an endotracheal tube, the phospholipids spread along the air-liquid interface of the alveoli. This reduces surface tension, preventing the alveoli from collapsing at the end of each breath. By stabilizing the alveoli, SURVANTA improves lung compliance, meaning the lungs become easier to inflate. This, in turn, reduces the work of breathing for the infant and improves gas exchange, leading to increased oxygen levels in the blood and decreased carbon dioxide levels.
• The surfactant-associated proteins SP-B and SP-C play a crucial role in the proper functioning of SURVANTA. SP-B helps to spread the phospholipids rapidly across the alveolar surface and is essential for the formation of a stable surfactant film. SP-C also contributes to the spreading and stability of the surfactant layer. These proteins ensure that the surfactant effectively reduces surface tension throughout the lungs.
• In essence, SURVANTA works by providing a replacement for the missing or deficient natural surfactant in premature infants with RDS. This replacement surfactant lines the alveoli, reduces surface tension, and stabilizes the air sacs, allowing the lungs to inflate properly and facilitating effective gas exchange. By improving lung function, SURVANTA significantly reduces the severity of RDS and improves the chances of survival and long-term health for premature infants.

While SURVANTA (beractant) Injection can be life-saving for premature infants with Respiratory Distress Syndrome (RDS), it's important to be aware of potential side effects. These can range from common to rare, and it's crucial to discuss any concerns with your doctor. **Common Side Effects (occurring in a significant number of patients):** * **Bradycardia (Slow Heart Rate):** A temporary slowing of the heart rate may occur during administration. * **Decreased Oxygen Saturation:** Oxygen levels in the blood may temporarily decrease. * **Endotracheal Tube Reflux:** The medication may back up into the endotracheal tube. * **Pallor (Paleness):** The infant's skin may appear paler than usual. * **Vasoconstriction:** Narrowing of blood vessels. **Less Common Side Effects (occurring in a smaller number of patients):** * **Apnea (Temporary Cessation of Breathing):** Breathing may stop for a short period. * **Pulmonary Hemorrhage:** Bleeding in the lungs. * **Mucus Plugging:** Blockage of the endotracheal tube with mucus. **Rare Side Effects (occurring very rarely):** * **Infection:** Introduction of infection. * **Post-treatment complications:** Complications arising after the treatment of this medicine **Important Considerations:** * This is not an exhaustive list, and other side effects may occur. * The healthcare team will closely monitor the infant for any adverse reactions during and after SURVANTA administration. * Report any unusual signs or symptoms to the medical staff immediately. * The benefits of SURVANTA in treating RDS usually outweigh the potential risks of side effects. **Tags:** SURVANTA, beractant, side effects, Respiratory Distress Syndrome, RDS, premature infants, bradycardia, apnea, pulmonary hemorrhage, mucus plugging, decreased oxygen saturation, endotracheal tube reflux, pallor, vasoconstriction, infection, post-treatment complications

• SURVANTA is administered in a neonatal intensive care unit (NICU) setting by trained medical professionals. Since the medication is crucial for premature infants with respiratory distress syndrome, a missed dose is unlikely as the dosing schedule is closely monitored. If a dose is inadvertently missed, the medical team will assess the infant's condition and administer the dose as soon as possible, guided by established medical protocols and the infant's clinical needs.

• Keep SURVANTA 25MG INJ 8ML away from the reach of children and pets.
• Store SURVANTA 25MG INJ 8ML in a refrigerator (2 - 8°C). Do not freeze.

• **Understanding Surfactant Replacement Therapy:** SURVANTA® is a lung surfactant used to treat and prevent Respiratory Distress Syndrome (RDS) in premature infants. It helps reduce surface tension in the lungs, allowing them to inflate more easily.
• **Dosage and Administration:** SURVANTA® is administered intratracheally (directly into the trachea/windpipe). Dosage is based on the infant's birth weight and is typically given in multiple doses. Administration should only be performed by trained medical personnel.
• **Monitoring During Administration:** Closely monitor the infant's heart rate, blood pressure, and oxygen saturation during and after SURVANTA® administration. Temporary changes in these vital signs are common, and medical staff are prepared to manage them.
• **Potential Side Effects:** While SURVANTA® is generally safe, potential side effects can include bradycardia (slow heart rate), decreased oxygen saturation, and airway obstruction. The medical team is equipped to handle these events promptly.
• **Storage and Handling:** SURVANTA® requires refrigeration. Before administration, it should be warmed slowly to room temperature, avoiding rapid heating methods. Unopened vials should be protected from light.
• **Importance of Supportive Care:** SURVANTA® is most effective when combined with other supportive measures, such as mechanical ventilation and oxygen therapy. These therapies help stabilize the infant's condition and optimize the benefits of surfactant replacement.
• **Educating Parents:** Although the administration is done by medical professionals, parents should be informed about RDS, SURVANTA®, and the expected course of treatment. Understanding the process can help alleviate anxiety and promote informed decision-making.
• **Avoid Shaking the Vial:** Gently swirl the vial to ensure the medication is uniformly dispersed. Avoid vigorous shaking, as this can damage the surfactant lipids.
• **Multiple Doses May Be Necessary:** Depending on the infant's response, repeat doses of SURVANTA® may be required. The medical team will assess the infant's condition and determine the need for additional doses.
• **Documenting the Procedure:** Meticulous documentation of the administration process, including dosage, vital signs, and any adverse events, is crucial for tracking the infant's progress and ensuring optimal care.

• SURVANTA 25MG INJECTION 8 ML is administered directly into the lungs of premature infants by medical professionals. As such, it does not interact with food. It is crucial to follow the medical professional’s guidance regarding infant feeding schedules.